{"id":"indapamide","rwe":[{"pmid":"41746376","year":"2026","title":"Pure vs. mixed calcium oxalate nephrolithiasis: metabolic determinants and stratified management strategies.","finding":"","journal":"World journal of urology","studyType":"Clinical Study"},{"pmid":"41728364","year":"2025","title":"2024 Thai guidelines on the treatment of hypertension.","finding":"","journal":"Asian biomedicine : research, reviews and news","studyType":"Clinical Study"},{"pmid":"41667119","year":"2026","title":"Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.","finding":"","journal":"European heart journal","studyType":"Clinical Study"},{"pmid":"41656849","year":"2026","title":"Effectiveness of Indapamide Prolonged-Release and Perindopril Versus Perindopril Monotherapy for Treated Uncontrolled Hypertension: A Target Trial Emulation.","finding":"","journal":"Pharmacoepidemiology and drug safety","studyType":"Clinical Study"},{"pmid":"41593840","year":"2026","title":"Widaplik: A Fixed-Dose Triple Combination for Initial Hypertension Therapy.","finding":"","journal":"Cardiology in review","studyType":"Clinical Study"}],"_fda":{"id":"7c1bd14b-7f8f-4ad6-9c3c-e6a0d9aad1cf","set_id":"0687ed93-4761-4f9c-887d-95309c03f60e","openfda":{"nui":["N0000175359","N0000175420"],"upc":["0316571875016","0316571876013"],"unii":["F089I0511L"],"route":["ORAL"],"rxcui":["197815","197816"],"spl_id":["7c1bd14b-7f8f-4ad6-9c3c-e6a0d9aad1cf"],"brand_name":["Indapamide"],"spl_set_id":["0687ed93-4761-4f9c-887d-95309c03f60e"],"package_ndc":["16571-875-01","16571-876-01"],"product_ndc":["16571-875","16571-876"],"generic_name":["INDAPAMIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Increased Diuresis [PE]"],"substance_name":["INDAPAMIDE"],"pharm_class_epc":["Thiazide-like Diuretic [EPC]"],"manufacturer_name":["Rising Pharma Holdings, Inc."],"application_number":["ANDA074461"],"is_original_packager":[true]},"version":"2","warnings":["WARNINGS Severe cases of hyponatremia, accompanied by hypokalemia have been reported with recommended doses of indapamide. This occurred primarily in elderly females. (See PRECAUTIONS , Geriatric Use .) This appears to be dose related. Also, a large case-controlled pharmacoepidemiology study indicates that there is an increased risk of hyponatremia with indapamide 2.5 mg and 5 mg doses. Hyponatremia considered possibly clinically significant (< 125 mEq/L) has not been observed in clinical trials with the 1.25 mg dosage (see PRECAUTIONS ). Thus, patients should be started at the 1.25 mg dose and maintained at the lowest possible dose. (See DOSAGE AND ADMINISTRATION .) Hypokalemia occurs commonly with diuretics (see ADVERSE REACTIONS, hypokalemia ), and electrolyte monitoring is essential, particularly in patients who would be at increased risk from hypokalemia, such as those with cardiac arrhythmias or who are receiving concomitant cardiac glycosides. In general, diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of lithium toxicity. Read prescribing information for lithium preparations before use of such concomitant therapy."],"pregnancy":["Pregnancy : Teratogenic Effects : Reproduction studies have been performed in rats, mice and rabbits at doses up to 6,250 times the therapeutic human dose and have revealed no evidence of impaired fertility or harm to the fetus due to indapamide. Postnatal development in rats and mice was unaffected by pretreatment of parent animals during gestation. There are, however, no adequate and well-controlled studies in pregnant women. Moreover, diuretics are known to cross the placental barrier and appear in cord blood. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. There may be hazards associated with this use such as fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in the adult."],"overdosage":["OVERDOSAGE Symptoms of overdosage include nausea, vomiting, weakness, gastrointestinal disorders and disturbances of electrolyte balance. In severe instances, hypotension and depressed respiration may be observed. If this occurs, support of respiration and cardiac circulation should be instituted. There is no specific antidote. An evacuation of the stomach is recommended by emesis and gastric lavage after which the electrolyte and fluid balance should be evaluated carefully."],"description":["DESCRIPTION Indapamide is an oral antihypertensive/diuretic. Its molecule contains both a polar sulfamoyl chlorobenzamide moiety and a lipid-soluble methylindoline moiety. It differs chemically from the thiazides in that it does not possess the thiazide ring system and contains only one sulfonamide group. The chemical name of indapamide is 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoyl benzamide, and its molecular weight is 365.8. The compound is a weak acid, pKa=9.35±0.60, and is soluble in methanol, in acetonitrile, in glacial acetic acid, and in ethyl acetate; very slightly soluble in ether and in chloroform; practically insoluble in water. It is a white to off- white, crystalline powder. Each tablet, for oral administration, contains 1.25 mg or 2.5 mg of indapamide, USP and the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium lauryl sulfate, titanium dioxide and triacetin. Additionally, the 1.25 mg product contains D&C Red# 30/ Helendon pink aluminum lake. indapamide-struct"],"precautions":["PRECAUTIONS General : Hypokalemia, Hyponatremia, and Other Fluid and Electrolyte Imbalances: Periodic determinations of serum electrolytes should be performed at appropriate intervals. In addition, patients should be observed for clinical signs of fluid or electrolyte imbalance, such as hyponatremia, hypochloremic alkalosis, or hypokalemia. Warning signs include dry mouth, thirst, weakness, fatigue, lethargy, drowsiness, restlessness, muscle pains or cramps, hypotension, oliguria, tachycardia, and gastrointestinal disturbance. Electrolyte determinations are particularly important in patients who are vomiting excessively or receiving parenteral fluids, in patients subject to electrolyte imbalance (including those with heart failure, kidney disease, and cirrhosis), and in patients on a salt-restricted diet. The risk of hypokalemia secondary to diuresis and natriuresis is increased when larger doses are used, when the diuresis is brisk, when severe cirrhosis is present and during concomitant use of corticosteroids or ACTH. Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Hypokalemia can sensitize or exaggerate the response of the heart to the toxic effects of digitalis, such as increased ventricular irritability. Dilutional hyponatremia may occur in edematous patients; the appropriate treatment is restriction of water rather than administration of salt, except in rare instances when the hyponatremia is life threatening. However, in actual salt depletion, appropriate replacement is the treatment of choice. Any chloride deficit that may occur during treatment is generally mild and usually does not require specific treatment except in extraordinary circumstances as in liver or renal disease. Thiazide-like diuretics have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Hyperuricemia and Gout: Serum concentrations of uric acid increased by an average of 0.69 mg/100 mL in patients treated with indapamide 1.25 mg, and by an average of 1.0 mg/100 mL in patients treated with indapamide 2.5 mg and 5.0 mg, and frank gout may be precipitated in certain patients receiving indapamide (see ADVERSE REACTIONS below). Serum concentrations of uric acid should, therefore, be monitored periodically during treatment. Renal Impairment : Indapamide, like the thiazides, should be used with caution in patients with severe renal disease, as reduced plasma volume may exacerbate or precipitate azotemia. If progressive renal impairment is observed in a patient receiving indapamide, withholding or discontinuing diuretic therapy should be considered. Renal function tests should be performed periodically during treatment with indapamide. Impaired Hepatic Function : Indapamide, like the thiazides, should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Glucose Tolerance : Latent diabetes may become manifest and insulin requirements in diabetic patients may be altered during thiazide administration. A mean increase in glucose of 6.47 mg/dL was observed in patients treated with indapamide 1.25 mg, which was not considered clinically significant in these trials. Serum concentrations of glucose should be monitored routinely during treatment with indapamide. Calcium Excretion : Calcium excretion is decreased by diuretics pharmacologically related to indapamide. After six to eight weeks of indapamide 1.25 mg treatment and in long-term studies of hypertensive patients with higher doses of indapamide, however, serum concentrations of calcium increased only slightly with indapamide. Prolonged treatment with drugs pharmacologically related to indapamide may in rare instances be associated with hypercalcemia and hypophosphatemia secondary to physiologic changes in the parathyroid gland; however, the common complications of hyperparathyroidism, such as renal lithiasis, bone resorption, and peptic ulcer, have not been seen. Treatment should be discontinued before tests for parathyroid function are performed. Like the thiazides, indapamide may decrease serum PBI levels without signs of thyroid disturbance. Interaction with Systemic Lupus Erythematosus : Thiazides have exacerbated or activated systemic lupus erythematosus and this possibility should be considered with indapamide as well. Acute Angle-Closure Glaucoma, Acute Myopia, and Choroidal Effusion: Sulfonamide or sulfonamide-derivative drugs, like indapamide, can cause an idiosyncratic reaction resulting in acute angle-closure glaucoma and elevated intraocular pressure with or without a noticeable acute myopic shift and/or choroidal effusions. Symptoms may include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated, the angle-closure glaucoma may result in permanent visual field loss. The primary treatment is to discontinue indapamide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. Drug Interactions Other Antihypertensives : Indapamide may add to or potentiate the action of other antihypertensive drugs. In limited controlled trials that compared the effect of indapamide combined with other antihypertensive drugs with the effect of the other drugs administered alone, there was no notable change in the nature or frequency of adverse reactions associated with the combined therapy. Lithium : See WARNINGS . Post-Sympathectomy Patient : The antihypertensive effect of the drug may be enhanced in the post-sympathectomized patient. Norepinephrine : Indapamide, like the thiazides, may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Carcinogenesis, Mutagenesis, Impairment of Fertility Both mouse and rat lifetime carcinogenicity studies were conducted. There was no significant difference in the incidence of tumors between the indapamide-treated animals and the control groups. Pregnancy : Teratogenic Effects : Reproduction studies have been performed in rats, mice and rabbits at doses up to 6,250 times the therapeutic human dose and have revealed no evidence of impaired fertility or harm to the fetus due to indapamide. Postnatal development in rats and mice was unaffected by pretreatment of parent animals during gestation. There are, however, no adequate and well-controlled studies in pregnant women. Moreover, diuretics are known to cross the placental barrier and appear in cord blood. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. There may be hazards associated with this use such as fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in the adult. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because most drugs are excreted in human milk, if use of this drug is deemed essential, the patient should stop nursing. Pediatric Use : Safety and effectiveness of indapamide in pediatric patients have not been established. Geriatric Use : Clinical studies of indapamide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Severe cases of hyponatremia, accompanied by hypokalemia have been reported with recommended doses of indapamide in elderly females (see WARNINGS )."],"how_supplied":["HOW SUPPLIED Indapamide Tablets, USP are available containing 1.25 mg or 2.5 mg of indapamide, USP. The 1.25 mg tablets are pink, film coated, round, biconvex, beveled edge tablet debossed with “875” on one side of the tablet and plain on the other side. They are available as follows: NDC 16571-875-01 bottles of 100 tablets The 2.5 mg tablets are white, film coated, round, biconvex, beveled edge tablet debossed with “876” on one side of the tablet and plain on the other side. They are available as follows: NDC 16571-876-01 bottles of 100 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Revised: 04/2023 200653 PIR87610-01"],"geriatric_use":["Geriatric Use : Clinical studies of indapamide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Severe cases of hyponatremia, accompanied by hypokalemia have been reported with recommended doses of indapamide in elderly females (see WARNINGS )."],"pediatric_use":["Pediatric Use : Safety and effectiveness of indapamide in pediatric patients have not been established."],"effective_time":"20230626","nursing_mothers":["Nursing Mothers: It is not known whether this drug is excreted in human milk. Because most drugs are excreted in human milk, if use of this drug is deemed essential, the patient should stop nursing."],"adverse_reactions":["ADVERSE REACTIONS Most adverse effects have been mild and transient. The clinical adverse reactions listed in Table 1 represent data from Phase II/III placebo-controlled studies (306 patients given indapamide 1.25 mg). The clinical adverse reactions listed in Table 2 represent data from Phase II placebo-controlled studies and long-term controlled clinical trials (426patients given indapamide 2.5 mg or 5.0 mg). The reactions are arranged into two groups: 1) a cumulative incidence equal to or greater than 5%; 2)a cumulative incidence less than 5%. Reactions are counted regardless of relation to drug. TABLE 1: Adverse Reaction from Studies of 1.25mg Incidence ≥ 5% Incidence < 5%* BODY AS A WHOLE Headache Asthenia Infection Flu Syndrome Pain Abdominal Pain Back Pain Chest Pain GASTROINTESTINAL SYSTEM Constipation Diarrhea Dyspepsia Nausea METABOLIC SYSTEM Peripheral Edema CENTRAL NERVOUS SYSTEM Nervousness Dizziness Hypertonia RESPIRATORY SYSTEM Cough RHINITIS Pharyngitis Sinusitis SPECIAL SENSES Conjunctivitis *OTHER All other clinical adverse reactions occurred at an incidence of <1%. Approximately 4% of patients given indapamide 1.25 mg compared to 5% of the patients given placebo discontinued treatment in the trials of up to eight weeks because of adverse reactions. In controlled clinical trials of six to eight weeks in duration, 20% of patients receiving indapamide 1.25 mg, 61% of patients receiving indapamide 5.0 mg, and 80% of patients receiving indapamide 10.0 mg had at least one potassium value below 3.4 mEq/L. In the indapamide 1.25 mg group, about 40% of those patients who reported hypokalemia as a laboratory adverse event returned to normal serum potassium values without intervention. Hypokalemia with concomitant clinical signs or symptoms occurred in 2% of patients receiving indapamide 1.25 mg. TABLE 2: Adverse Reactions from Studies of 2.5 mg and 5.0 mg Incidence ≥ 5% Incidence < 5% CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Headache Lightheadedness Dizziness Drowsiness Fatigue, weakness, loss of energy, lethargy, tiredness, or malaise Vertigo Insomnia Depression Muscle cramps or spasm, or numbness of the extremities Blurred Visoin Nervousness, tension, anxiety, irritability, or agitation GASTROINTESTINAL SYSTEM Constipation Nausea Vomiting Diarrhea Gastric irritation Abdominal pain or cramps Anorexia CARDIOVASCULAR SYSTEM Orthostatic hypotension Premature ventricular contractions Irregular heart beat Palpitations GENITOURINARY SYSTEM Frequency of urination Nocturia Polyuria DERMATOLOGIC/HYPERSENSITIVITY Rash Hives Pruritus Vasculitis OTHER Impotence or reduced libido Rhinorrhea Flushing Hyperuricemia Hyperglycemia Hyponatremia Hypochloremia Increase in serum urea nitrogen (BUN) or creatinine Glycosuria Weight loss Dry mouth Tingling of extremities Because most of these data are from long-term studies (up to 40 weeks of treatment), it is probable that many of the adverse experiences reported are due to causes other than the drug. Approximately 10% of patients given indapamide discontinued treatment in long-term trials because of reactions either related or unrelated to the drug. Hypokalemia with concomitant clinical signs or symptoms occurred in 3% of patients receiving indapamide 2.5 mg q.d. and 7% of patients receiving indapamide 5 mg q.d. In long-term controlled clinical trials comparing the hypokalemic effects of daily doses of indapamide and hydrochlorothiazide, however, 47% of patients receiving indapamide 2.5 mg, 72% of patients receiving indapamide 5 mg, and 44% of patients receiving hydrochlorothiazide 50 mg had at least one potassium value (out of a total of 11 taken during the study) below 3.5 mEq/L. In the indapamide 2.5 mg group, over 50% of those patients returned to normal serum potassium values without intervention. In clinical trials of six to eight weeks, the mean changes in selected values were as shown in the tables below. Mean Changes from Baseline after 8 Weeks of Treatment - 1.25 mg Serum Electrolytes (mEq/ L) Serum Uric Acid (mg/dL) BUN (mg/dL) Potassium Sodium Chloride Indapamide 1.25 mg (n=255 to 257) -0.28 -0.63 -2.60 0.69 1.46 Placebo (n=263 to 266) 0.00 -0.11 -0.21 0.06 0.06 No patients receiving indapamide 1.25 mg experienced hyponatremia considered possibly clinically significant (< 125 mEq/L). Mean Changes from Baseline after 40 Weeks of Treatment - 2.5 mg and 5.0 mg Serum Electrolytes (mEq/L) Serum Uric Acid (mg/dL) BUN (mg/dL) Potassium Sodium Chloride Indapamide 2.5 mg (n=76) -0.4 -0.6 -3.6 0.7 -0.1 Indapamide 5.0 mg (n=81) -0.6 -0.7 -5.1 1.1 1.4 The following reactions have been reported with clinical usage of indapamide: jaundice (intrahepatic cholestatic jaundice), hepatitis, pancreatitis and abnormal liver function tests. These reactions were reversible with discontinuance of the drug. Also reported are erythema multiforme, Stevens-Johnson Syndrome, bullous eruptions, purpura, photosensitivity, fever, pneumonitis, anaphylactic reactions, agranulocytosis, leukopenia, thrombocytopenia and aplastic anemia. Other adverse reactions reported with antihypertensive/diuretics are necrotizing angiitis, respiratory distress, sialadenitis, xanthopsia. Postmarketing Experience Eye Disorders: Choroidal effusion, acute myopia, and angle-closure glaucoma (frequency not known). 1 1 Module 2.5 SER-indapamide-choroidal effusion-acute myopia and angleclosure glaucoma-Jul2020 To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www. fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Anuria. Known hypersensitivity to indapamide or to other sulfonamide-derived drugs."],"drug_interactions":["Drug Interactions Other Antihypertensives : Indapamide may add to or potentiate the action of other antihypertensive drugs. In limited controlled trials that compared the effect of indapamide combined with other antihypertensive drugs with the effect of the other drugs administered alone, there was no notable change in the nature or frequency of adverse reactions associated with the combined therapy. Lithium : See WARNINGS . Post-Sympathectomy Patient : The antihypertensive effect of the drug may be enhanced in the post-sympathectomized patient. Norepinephrine : Indapamide, like the thiazides, may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use."],"general_precautions":["General : Hypokalemia, Hyponatremia, and Other Fluid and Electrolyte Imbalances: Periodic determinations of serum electrolytes should be performed at appropriate intervals. In addition, patients should be observed for clinical signs of fluid or electrolyte imbalance, such as hyponatremia, hypochloremic alkalosis, or hypokalemia. Warning signs include dry mouth, thirst, weakness, fatigue, lethargy, drowsiness, restlessness, muscle pains or cramps, hypotension, oliguria, tachycardia, and gastrointestinal disturbance. Electrolyte determinations are particularly important in patients who are vomiting excessively or receiving parenteral fluids, in patients subject to electrolyte imbalance (including those with heart failure, kidney disease, and cirrhosis), and in patients on a salt-restricted diet. The risk of hypokalemia secondary to diuresis and natriuresis is increased when larger doses are used, when the diuresis is brisk, when severe cirrhosis is present and during concomitant use of corticosteroids or ACTH. Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Hypokalemia can sensitize or exaggerate the response of the heart to the toxic effects of digitalis, such as increased ventricular irritability. Dilutional hyponatremia may occur in edematous patients; the appropriate treatment is restriction of water rather than administration of salt, except in rare instances when the hyponatremia is life threatening. However, in actual salt depletion, appropriate replacement is the treatment of choice. Any chloride deficit that may occur during treatment is generally mild and usually does not require specific treatment except in extraordinary circumstances as in liver or renal disease. Thiazide-like diuretics have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Hyperuricemia and Gout: Serum concentrations of uric acid increased by an average of 0.69 mg/100 mL in patients treated with indapamide 1.25 mg, and by an average of 1.0 mg/100 mL in patients treated with indapamide 2.5 mg and 5.0 mg, and frank gout may be precipitated in certain patients receiving indapamide (see ADVERSE REACTIONS below). Serum concentrations of uric acid should, therefore, be monitored periodically during treatment. Renal Impairment : Indapamide, like the thiazides, should be used with caution in patients with severe renal disease, as reduced plasma volume may exacerbate or precipitate azotemia. If progressive renal impairment is observed in a patient receiving indapamide, withholding or discontinuing diuretic therapy should be considered. Renal function tests should be performed periodically during treatment with indapamide. Impaired Hepatic Function : Indapamide, like the thiazides, should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Glucose Tolerance : Latent diabetes may become manifest and insulin requirements in diabetic patients may be altered during thiazide administration. A mean increase in glucose of 6.47 mg/dL was observed in patients treated with indapamide 1.25 mg, which was not considered clinically significant in these trials. Serum concentrations of glucose should be monitored routinely during treatment with indapamide. Calcium Excretion : Calcium excretion is decreased by diuretics pharmacologically related to indapamide. After six to eight weeks of indapamide 1.25 mg treatment and in long-term studies of hypertensive patients with higher doses of indapamide, however, serum concentrations of calcium increased only slightly with indapamide. Prolonged treatment with drugs pharmacologically related to indapamide may in rare instances be associated with hypercalcemia and hypophosphatemia secondary to physiologic changes in the parathyroid gland; however, the common complications of hyperparathyroidism, such as renal lithiasis, bone resorption, and peptic ulcer, have not been seen. Treatment should be discontinued before tests for parathyroid function are performed. Like the thiazides, indapamide may decrease serum PBI levels without signs of thyroid disturbance. Interaction with Systemic Lupus Erythematosus : Thiazides have exacerbated or activated systemic lupus erythematosus and this possibility should be considered with indapamide as well. Acute Angle-Closure Glaucoma, Acute Myopia, and Choroidal Effusion: Sulfonamide or sulfonamide-derivative drugs, like indapamide, can cause an idiosyncratic reaction resulting in acute angle-closure glaucoma and elevated intraocular pressure with or without a noticeable acute myopic shift and/or choroidal effusions. Symptoms may include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated, the angle-closure glaucoma may result in permanent visual field loss. The primary treatment is to discontinue indapamide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Indapamide is the first of a new class of antihypertensive/diuretics, the indolines. The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in blood within two hours. The oral administration of 5 mg (two 2.5 mg tablets) of indapamide to healthy male subjects produced peak concentrations of approximately 260 ng/mL of the drug in the blood within two hours. A minimum of 70% of a single oral dose is eliminated by the kidneys and an additional 23% by the gastrointestinal tract, probably including the biliary route. The half-life of indapamide in whole blood is approximately 14 hours. Indapamide is preferentially and reversibly taken up by the erythrocytes in the peripheral blood. The whole blood/plasma ratio is approximately 6:1 at the time of peak concentration and decreases to 3.5:1 at eight hours. From 71 to 79% of the indapamide in plasma is reversibly bound to plasma proteins. Indapamide is an extensively metabolized drug, with only about 7% of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration. The urinary elimination of 14 C-labeled indapamide and metabolites is biphasic with a terminal half-life of excretion of total radioactivity of 26 hours. In a parallel design double-blind, placebo controlled trial in hypertension, daily doses of indapamide between 1.25 mg and 10.0 mg produced dose related antihypertensive effects. Doses of 5.0 and 10.0 mg were not distinguishable from each other although each was differentiated from placebo and 1.25 mg indapamide. At daily doses of 1.25 mg, 5.0 mg and 10.0 mg, a mean decrease of serum potassium of 0.28, 0.61 and 0.76 mEq/L, respectively, was observed and uric acid increased by about 0.69 mg/100 mL. In other parallel design, dose-ranging clinical trials in hypertension and edema, daily doses of indapamide between 0.5 and 5.0 mg produced dose related effects. Generally, doses of 2.5 and 5.0 mg were not distinguishable from each other although each was differentiated from placebo and from 0.5 or 1.0 mg indapamide. At daily doses of 2.5 and 5.0 mg a mean decrease of serum potassium of 0.5 and 0.6 mEq/Liter, respectively, was observed and uric acid increased by about 1.0 mg/100 mL. At these doses, the effects of indapamide on blood pressure and edema are approximately equal to those obtained with conventional doses of other antihypertensive/diuretics. In hypertensive patients, daily doses of 1.25, 2.5 and 5.0 mg of indapamide have no appreciable cardiac inotropic or chronotropic effect. The drug decreases peripheral resistance with little or no effect on cardiac output, rate or rhythm. Chronic administration of indapamide to hypertensive patients has little or no effect on glomerular filtration rate or renal plasma flow. Indapamide had an antihypertensive effect in patients with varying degrees of renal impairment, although in general, diuretic effects declined as renal function decreased. In a small number of controlled studies, indapamide taken with other antihypertensive drugs such as hydralazine, propranolol, guanethidine and methyldopa, appeared to have the additive effect typical of thiazide-type diuretics."],"indications_and_usage":["INDICATIONS Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Usage in Pregnancy : The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS below). Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Indapamide is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate."],"adverse_reactions_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><caption>TABLE 1: Adverse Reaction from Studies of 1.25mg </caption><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Incidence &#x2265; 5%  </td><td styleCode=\"Rrule\" valign=\"middle\">Incidence &lt; 5%*  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> BODY AS A WHOLE </td><td styleCode=\"Rrule\" valign=\"middle\"> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Headache</td><td styleCode=\"Rrule\" valign=\"middle\"> Asthenia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Infection</td><td styleCode=\"Rrule\" valign=\"middle\"> Flu Syndrome </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Pain</td><td styleCode=\"Rrule\" valign=\"middle\"> Abdominal Pain </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Back Pain </td><td styleCode=\"Rrule\" valign=\"middle\"> Chest Pain </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"4\" valign=\"middle\"> GASTROINTESTINAL SYSTEM </td><td styleCode=\"Rrule\" valign=\"middle\"> Constipation</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Diarrhea</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Dyspepsia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Nausea</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> METABOLIC SYSTEM </td><td styleCode=\"Rrule\" valign=\"middle\"> Peripheral Edema </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> CENTRAL NERVOUS SYSTEM </td><td styleCode=\"Rrule\" valign=\"middle\"> Nervousness</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Dizziness</td><td styleCode=\"Rrule\" valign=\"middle\"> Hypertonia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> RESPIRATORY SYSTEM </td><td styleCode=\"Rrule\" valign=\"middle\"> Cough</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" valign=\"middle\"> RHINITIS</td><td styleCode=\"Rrule\" valign=\"middle\"> Pharyngitis</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Sinusitis</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> SPECIAL SENSES </td><td styleCode=\"Rrule\" valign=\"middle\"> Conjunctivitis</td></tr><tr><td styleCode=\"Lrule Rrule\" colspan=\"2\" valign=\"middle\"> *OTHER</td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><caption>TABLE 2: Adverse Reactions from Studies of 2.5 mg and 5.0 mg </caption><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Incidence &#x2265; 5%  </td><td styleCode=\"Rrule\" valign=\"middle\">Incidence &lt; 5%  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR </td><td styleCode=\"Rrule\" valign=\"middle\"> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Headache</td><td styleCode=\"Rrule\" valign=\"middle\"> Lightheadedness</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Dizziness</td><td styleCode=\"Rrule\" valign=\"middle\"> Drowsiness</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Fatigue, weakness, loss of energy, lethargy, tiredness, or malaise </td><td styleCode=\"Rrule\" valign=\"middle\"> Vertigo</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> </td><td styleCode=\"Rrule\" valign=\"middle\"> Insomnia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> </td><td styleCode=\"Rrule\" valign=\"middle\"> Depression</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Muscle cramps or spasm, or numbness of the extremities </td><td styleCode=\"Rrule\" valign=\"middle\"> Blurred Visoin </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Nervousness, tension, anxiety, irritability, or agitation </td><td styleCode=\"Rrule\" valign=\"middle\"> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"7\" valign=\"middle\"> GASTROINTESTINAL SYSTEM </td><td styleCode=\"Rrule\" valign=\"middle\"> Constipation</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Nausea</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Vomiting</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Diarrhea</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Gastric irritation </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Abdominal pain or cramps </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Anorexia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"4\" valign=\"middle\"> CARDIOVASCULAR SYSTEM </td><td styleCode=\"Rrule\" valign=\"middle\"> Orthostatic hypotension</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Premature ventricular contractions</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Irregular heart beat</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Palpitations</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"3\" valign=\"middle\"> GENITOURINARY SYSTEM</td><td styleCode=\"Rrule\" valign=\"middle\"> Frequency of urination</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Nocturia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Polyuria</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"4\" valign=\"middle\"> DERMATOLOGIC/HYPERSENSITIVITY</td><td styleCode=\"Rrule\" valign=\"middle\"> Rash</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Hives</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Pruritus</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Vasculitis</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"12\" valign=\"middle\"> OTHER</td><td styleCode=\"Rrule\" valign=\"middle\"> Impotence or reduced libido</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Rhinorrhea</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Flushing</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Hyperuricemia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Hyperglycemia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Hyponatremia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Hypochloremia</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Increase in serum urea nitrogen (BUN) or creatinine</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Glycosuria</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Weight loss</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Dry mouth</td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Tingling of extremities</td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><caption>Mean Changes from Baseline after 8 Weeks of Treatment - 1.25 mg </caption><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> </td><td styleCode=\"Rrule\" colspan=\"3\" valign=\"middle\">Serum Electrolytes (mEq/ L)  </td><td styleCode=\"Rrule\" rowspan=\"2\" valign=\"middle\"> Serum Uric Acid  (mg/dL)</td><td styleCode=\"Rrule\" rowspan=\"2\" valign=\"middle\"> BUN  (mg/dL)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> </td><td styleCode=\"Rrule\" valign=\"middle\"> Potassium </td><td styleCode=\"Rrule\" valign=\"middle\"> Sodium </td><td styleCode=\"Rrule\" valign=\"middle\"> Chloride </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Indapamide 1.25 mg  (n=255 to 257) </td><td styleCode=\"Rrule\" valign=\"middle\"> -0.28</td><td styleCode=\"Rrule\" valign=\"middle\"> -0.63</td><td styleCode=\"Rrule\" valign=\"middle\"> -2.60</td><td styleCode=\"Rrule\" valign=\"middle\"> 0.69</td><td styleCode=\"Rrule\" valign=\"middle\"> 1.46</td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Placebo  (n=263 to 266) </td><td styleCode=\"Rrule\" valign=\"middle\"> 0.00</td><td styleCode=\"Rrule\" valign=\"middle\"> -0.11</td><td styleCode=\"Rrule\" valign=\"middle\"> -0.21</td><td styleCode=\"Rrule\" valign=\"middle\"> 0.06</td><td styleCode=\"Rrule\" valign=\"middle\"> 0.06</td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><caption>Mean Changes from Baseline after 40 Weeks of Treatment - 2.5 mg and 5.0 mg </caption><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> </td><td styleCode=\"Rrule\" colspan=\"3\" valign=\"middle\"> Serum Electrolytes (mEq/L)</td><td styleCode=\"Rrule\" rowspan=\"2\" valign=\"middle\">Serum Uric Acid  (mg/dL)  </td><td styleCode=\"Rrule\" rowspan=\"2\" valign=\"middle\"> BUN  (mg/dL)</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\"> </td><td styleCode=\"Rrule\" valign=\"middle\"> Potassium</td><td styleCode=\"Rrule\" valign=\"middle\">Sodium  </td><td styleCode=\"Rrule\" valign=\"middle\"> Chloride</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Indapamide 2.5 mg   (n=76)  </td><td styleCode=\"Rrule\" valign=\"middle\"> -0.4</td><td styleCode=\"Rrule\" valign=\"middle\"> -0.6</td><td styleCode=\"Rrule\" valign=\"middle\"> -3.6</td><td styleCode=\"Rrule\" valign=\"middle\"> 0.7</td><td styleCode=\"Rrule\" valign=\"middle\"> -0.1</td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\"> Indapamide 5.0 mg  (n=81)</td><td styleCode=\"Rrule\" valign=\"middle\"> -0.6</td><td styleCode=\"Rrule\" valign=\"middle\"> -0.7</td><td styleCode=\"Rrule\" valign=\"middle\"> -5.1</td><td styleCode=\"Rrule\" valign=\"middle\"> 1.1</td><td styleCode=\"Rrule\" valign=\"middle\"> 1.4</td></tr></tbody></table>"],"dosage_and_administration":["DOSAGE & ADMINISTRATION Hypertension : The adult starting indapamide dose for hypertension is 1.25 mg as a single daily dose taken in the morning. If the response to 1.25 mg is not satisfactory after 4 weeks, the daily dose may be increased to 2.5 mg taken once daily. If the response to 2.5 mg is not satisfactory after 4 weeks, the daily dose may be increased to 5.0 mg taken once daily, but adding another antihypertensive should be considered. Edema of Congestive Heart Failure : The adult starting indapamide dose for edema of congestive heart failure is 2.5 mg as a single daily dose taken in the morning. If the response to 2.5 mg is not satisfactory after one week, the daily dose may be increased to 5.0 mg taken once daily. If the antihypertensive response to indapamide is insufficient, indapamide may be combined with other antihypertensive drugs, with careful monitoring of blood pressure. It is recommended that the usual dose of other agents be reduced by 50% during initial combination therapy. As the blood pressure response becomes evident, further dosage adjustments may be necessary. In general, doses of 5.0 mg and larger have not appeared to provide additional effects on blood pressure or heart failure, but are associated with a greater degree of hypokalemia. There is minimal clinical trial experience in patients with doses greater than 5.0 mg once a day."],"spl_product_data_elements":["Indapamide Indapamide INDAPAMIDE INDAPAMIDE ANHYDROUS LACTOSE SILICON DIOXIDE MAGNESIUM STEARATE POLYDEXTROSE STARCH, CORN SODIUM LAURYL SULFATE TITANIUM DIOXIDE TRIACETIN D&C RED NO. 30 HYPROMELLOSE 2910 (6 MPA.S) HYPROMELLOSE 2910 (3 MPA.S) MICROCRYSTALLINE CELLULOSE 102 POLYETHYLENE GLYCOL 8000 875 Indapamide Indapamide INDAPAMIDE INDAPAMIDE ANHYDROUS LACTOSE SILICON DIOXIDE MAGNESIUM STEARATE POLYDEXTROSE STARCH, CORN SODIUM LAURYL SULFATE TITANIUM DIOXIDE TRIACETIN HYPROMELLOSE 2910 (6 MPA.S) HYPROMELLOSE 2910 (3 MPA.S) HYPROMELLOSE 2910 (50 MPA.S) MICROCRYSTALLINE CELLULOSE 102 POLYETHYLENE GLYCOL 8000 876"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 1.25 mg: NDC: 16571-875-01 Indapamide Tablets USP, 1.25 mg Rx only 100 Tablets 2.5 mg: NDC: 16571-876-01 Indapamide Tablets USP, 2.5 mg Rx only 100 Tablets indapamide-label1 indapamide-label2"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Both mouse and rat lifetime carcinogenicity studies were conducted. There was no significant difference in the incidence of tumors between the indapamide-treated animals and the control groups."]},"tags":[{"label":"Thiazide-like Diuretic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Carbonic anhydrase 7","category":"target"},{"label":"CA7","category":"gene"},{"label":"CA12","category":"gene"},{"label":"SLC12A3","category":"gene"},{"label":"C03BA11","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Edema","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Approved 1980s","category":"decade"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"},{"label":"Sodium Chloride Symporter Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"HYPONATRAEMIA","source":"FDA FAERS","actionTaken":"1286 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"925 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"899 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"876 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"863 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"843 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"782 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"756 reports"},{"date":"","signal":"HYPOKALAEMIA","source":"FDA FAERS","actionTaken":"746 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"699 reports"}],"drugInteractions":[{"url":"/drug/lithium","drug":"lithium","action":"Avoid combination","effect":"May interact with Lithium","source":"DrugCentral","drugSlug":"lithium"}],"commonSideEffects":[{"effect":"Hypokalemia","drugRate":"47%","severity":"serious","_validated":true},{"effect":"Headache","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Constipation","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Diarrhea","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Dizziness","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Lightheadedness","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Drowsiness","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Fatigue","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Vertigo","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Insomnia","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Muscle cramps","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Depression","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Blurred Vision","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Nervousness","drugRate":"≥20%","severity":"common","_validated":true},{"effect":"Abdominal pain","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Back pain","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Chest pain","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Rhinitis","drugRate":"reported","severity":"unknown"},{"effect":"Conjunctivitis","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute nephropathy","Anuria","Dehydration","Diabetes mellitus","Disease of liver","Gout","Hyperparathyroidism","Hyperuricemia","Hypokalemia","Hyponatremia","Oliguria","Sympathectomy"],"specialPopulations":{"Pregnancy":"There are, however, no adequate and well-controlled studies in pregnant women. Moreover, diuretics are known to cross the placental barrier and appear","Geriatric use":"In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.","Paediatric use":"Safety and effectiveness of indapamide in pediatric patients have not been established."}},"trials":[],"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1133/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$41","description":"INDAPAMIDE 1.25 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=INDAPAMIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:40:02.675461+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Indapamide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:40:09.784380+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:40:08.393547+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:40:01.797253+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INDAPAMIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:40:08.750967+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:58.185880+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:58.185916+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:58.185922+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:40:10.231688+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thiazide-sensitive sodium-chloride cotransporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:40:09.784313+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL406/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:40:09.446231+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA074461","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:39:58.185925+00:00"}},"allNames":"lozol","offLabel":[],"synonyms":["metindamide","indapamide hemihydrate","indapamide","flupamid","indaflex","indamide","indamol","veroxil","(+/-)-Indapamide"],"timeline":[{"date":"1983-07-06","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1996-04-29","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"aiSummary":"Lozol (Indapamide) is a thiazide-like diuretic medication originally developed by Sanofi Aventis Us. It targets carbonic anhydrase 7 and is used to treat edema and hypertensive disorders. Lozol is a small molecule modality with 90% bioavailability and was FDA approved in 1983. The medication is now off-patent with multiple generic manufacturers. As a diuretic, Lozol works by increasing urine production to reduce fluid buildup in the body.","approvals":[{"date":"1983-07-06","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Lozol","ecosystem":[{"indication":"Edema","otherDrugs":[{"name":"acetazolamide","slug":"acetazolamide","company":"Teva Branded Pharm"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"}],"globalPrevalence":200000},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Carbonic anhydrase 7","novelty":"Follow-on","targets":[{"gene":"CA7","source":"DrugCentral","target":"Carbonic anhydrase 7","protein":"Carbonic anhydrase 7"},{"gene":"CA12","source":"DrugCentral","target":"Carbonic anhydrase 12","protein":"Carbonic anhydrase 12"},{"gene":"SLC12A3","source":"DrugCentral","target":"Solute carrier family 12 member 3","protein":"Solute carrier family 12 member 3"},{"gene":"CA9","source":"DrugCentral","target":"Carbonic anhydrase 9","protein":"Carbonic anhydrase 9"},{"gene":"CA13","source":"DrugCentral","target":"Carbonic anhydrase 13","protein":"Carbonic anhydrase 13"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase 2","protein":"Carbonic anhydrase 2"},{"gene":"CA4","source":"DrugCentral","target":"Carbonic anhydrase 4","protein":"Carbonic anhydrase 4"},{"gene":"CA6","source":"DrugCentral","target":"Carbonic anhydrase 6","protein":"Carbonic anhydrase 6"},{"gene":"CA5B","source":"DrugCentral","target":"Carbonic anhydrase 5B, mitochondrial","protein":"Carbonic anhydrase 5B, mitochondrial"},{"gene":"CA5A","source":"DrugCentral","target":"Carbonic anhydrase 5A, mitochondrial","protein":"Carbonic anhydrase 5A, mitochondrial"}],"modality":"Small Molecule","drugClass":"Thiazide-like Diuretic [EPC]","explanation":"","oneSentence":"","technicalDetail":"Indapamide acts as a carbonic anhydrase inhibitor, specifically targeting carbonic anhydrase 7, which is involved in the regulation of fluid balance and electrolyte homeostasis in the body."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Indapamide","title":"Indapamide","extract":"Indapamide is a thiazide-like diuretic drug used in the treatment of hypertension, as well as decompensated heart failure. Combination preparations with perindopril are available. The thiazide-like diuretics reduce risk of major cardiovascular events and heart failure in hypertensive patients compared with hydrochlorothiazide with a comparable incidence of adverse events. Both thiazide diuretics and thiazide-like diuretics are effective in reducing risk of stroke. Both drug classes appear to have comparable rates of adverse effects as other antihypertensives such as angiotensin II receptor blockers and dihydropyridine calcium channel blockers and lesser prevalence of side-effects when compared to ACE-inhibitors and non-dihydropyridine calcium channel blockers."},"commercial":{"launchDate":"1983","_launchSource":"DrugCentral (FDA 1983-07-06, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1433","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=INDAPAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INDAPAMIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Indapamide","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:03:55.900394","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:40:12.852486+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"quinethazone","drugSlug":"quinethazone","fdaApproval":"1963-04-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"chlortalidone","drugSlug":"chlortalidone","fdaApproval":"1960-04-07","relationship":"same-class"},{"drugName":"metolazone","drugSlug":"metolazone","fdaApproval":"1973-11-27","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"indapamide","indications":{"approved":[{"name":"Edema","source":"DrugCentral","snomedId":267038008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":200000,"prevalenceMethod":"curated","prevalenceSource":"Int Arch Allergy Immunol, 2025 (PMID:39827848)"},{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Sanofi Aventis Us","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"quinethazone","brandName":"quinethazone","genericName":"quinethazone","approvalYear":"1963","relationship":"same-class"},{"drugId":"chlortalidone","brandName":"chlortalidone","genericName":"chlortalidone","approvalYear":"1960","relationship":"same-class"},{"drugId":"metolazone","brandName":"metolazone","genericName":"metolazone","approvalYear":"1973","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":["Diabetes Mellitus","High Blood Pressure","Cardiovascular Diseases","Cognitive Impairment"],"enrollment":9476,"completionDate":"2026-05-31"},{"nctId":"NCT07421414","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions","status":"NOT_YET_RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2026-04-19","conditions":["Essential Hypertension"],"enrollment":48,"completionDate":"2026-06-17"},{"nctId":"NCT05780710","phase":"NA","title":"OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake","status":"RECRUITING","sponsor":"Aktiia SA","startDate":"2023-06-29","conditions":["Hypertension"],"enrollment":35,"completionDate":"2026-12-31"},{"nctId":"NCT00128518","phase":"PHASE4","title":"IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2004-10","conditions":["Hypertension"],"enrollment":139,"completionDate":"2010-09"},{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":["Apparent Resistant Hypertension","Hypertension","High Blood Pressure"],"enrollment":142,"completionDate":"2026-12-31"},{"nctId":"NCT07240909","phase":"PHASE4","title":"Antihypertensive Drug Selection Based on Hemodynamic Phenotypes","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-01","conditions":["Hypertension"],"enrollment":240,"completionDate":"2026-12"},{"nctId":"NCT07232966","phase":"PHASE3","title":"Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Yan Li","startDate":"2025-11-20","conditions":["Resistant Hypertension"],"enrollment":220,"completionDate":"2029-06-30"},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":["Hypertension"],"enrollment":663,"completionDate":"2024-09-13"},{"nctId":"NCT05365477","phase":"PHASE4","title":"Empiric Versus Selective Prevention Strategies for Kidney Stone Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-08-04","conditions":["Kidney Stones","Nephrolithiasis"],"enrollment":56,"completionDate":"2025-10-17"},{"nctId":"NCT02699645","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-09-28","conditions":["Intracerebral Haemorrhage (ICH)","Hypertension"],"enrollment":1671,"completionDate":"2025-08-27"},{"nctId":"NCT07034677","phase":"PHASE4","title":"Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism","status":"RECRUITING","sponsor":"Lars Rejnmark","startDate":"2025-08","conditions":["Hypoparathyroidism Post-surgical"],"enrollment":24,"completionDate":"2025-12"},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":["Hypertension","Obesity"],"enrollment":198,"completionDate":"2025-06-30"},{"nctId":"NCT07064525","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension","status":"ENROLLING_BY_INVITATION","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-12-05","conditions":["Hypertension (HTN)","NYHA Class III Heart Failure","NYHA Class IV Heart Failure","Diabete Mellitus"],"enrollment":252,"completionDate":"2026-02-28"},{"nctId":"NCT06259175","phase":"","title":"Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2024-05-01","conditions":["Arterial Hypertension","HTN"],"enrollment":396,"completionDate":"2025-06-01"},{"nctId":"NCT04518293","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-07-09","conditions":["Hypertension"],"enrollment":1385,"completionDate":"2023-09-01"},{"nctId":"NCT04518306","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-06-14","conditions":["Hypertension"],"enrollment":755,"completionDate":"2023-10-18"},{"nctId":"NCT00145925","phase":"PHASE3","title":"Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"The George Institute","startDate":"2001-06","conditions":["Diabetes Mellitus, Type 2"],"enrollment":11140,"completionDate":"2008-03"},{"nctId":"NCT06111885","phase":"PHASE2","title":"Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-10-01","conditions":["Kidney Stone"],"enrollment":99,"completionDate":"2027-06-30"},{"nctId":"NCT06012487","phase":"PHASE1","title":"Correlates and Control of Blood Pressure Variability","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-05-01","conditions":["Blood Pressure Variability"],"enrollment":10,"completionDate":"2026-12-31"},{"nctId":"NCT06826872","phase":"PHASE2","title":"Efficacy and Safety of SPC1001 in Patients With Essential Hypertension","status":"RECRUITING","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-06-12","conditions":["Hypertension, Essential","Cardiovascular Diseases","Cardiology"],"enrollment":252,"completionDate":"2025-12-30"},{"nctId":"NCT03640312","phase":"PHASE2","title":"Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-08-30","conditions":["Hypertension"],"enrollment":62,"completionDate":"2024-07-31"},{"nctId":"NCT05878561","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-11-09","conditions":["Essential Hypertension"],"enrollment":248,"completionDate":"2024-12-02"},{"nctId":"NCT05683301","phase":"PHASE4","title":"Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India","status":"COMPLETED","sponsor":"Centre for Chronic Disease Control, India","startDate":"2022-08-30","conditions":["Primary Hypertension"],"enrollment":1981,"completionDate":"2024-09-22"},{"nctId":"NCT05820880","phase":"PHASE3","title":"Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-05-06","conditions":["Hypertension"],"enrollment":532,"completionDate":"2022-02-23"},{"nctId":"NCT06500689","phase":"PHASE3","title":"To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2021-12-30","conditions":["Essential Hypertension"],"enrollment":366,"completionDate":"2024-05-24"},{"nctId":"NCT04647292","phase":"PHASE2","title":"European Blood Pressure Intensive Control After Stroke","status":"RECRUITING","sponsor":"University College Dublin","startDate":"2024-05-02","conditions":["Ischemic Stroke","Transient Ischemic Attack"],"enrollment":142,"completionDate":"2026-03"},{"nctId":"NCT05899920","phase":"NA","title":"Clinical One-stage Controlled Study of reSistant Arterial Hypertension for the desiGning of a personAlized Approach to Therapy","status":"RECRUITING","sponsor":"Ryazan State Medical University","startDate":"2022-03-11","conditions":["Resistant Arterial Hypertension"],"enrollment":190,"completionDate":"2024-12-31"},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":["Hypertension"],"enrollment":2500,"completionDate":"2025-12-31"},{"nctId":"NCT06212648","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-03-25","conditions":["Hypertension","Essential Hypertension"],"enrollment":253,"completionDate":"2023-01-27"},{"nctId":"NCT04036409","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients","status":"UNKNOWN","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-05","conditions":["Ischemic Stroke","Blood Pressure","Cognitive Impairment","Vascular Diseases"],"enrollment":4369,"completionDate":"2025-12"},{"nctId":"NCT02364089","phase":"NA","title":"Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2015-04-09","conditions":["Adrenal Incidentalomas"],"enrollment":78,"completionDate":"2022-11-23"},{"nctId":"NCT05377203","phase":"PHASE4","title":"Low-dose Quadruple Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-07-13","conditions":["Hypertension","Arterial Hypertension"],"enrollment":90,"completionDate":"2023-07-04"},{"nctId":"NCT05940909","phase":"PHASE1","title":"Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2023-06-24","conditions":["Bioequivalence"],"enrollment":50,"completionDate":"2023-11-17"},{"nctId":"NCT03814109","phase":"PHASE3","title":"Efficacy and Safety of Leningrado Association in the Treatment of Hypertension","status":"WITHDRAWN","sponsor":"EMS","startDate":"2022-04","conditions":["Arterial Hypertension"],"enrollment":0,"completionDate":"2024-01"},{"nctId":"NCT01620788","phase":"PHASE3","title":"Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment","status":"SUSPENDED","sponsor":"EMS","startDate":"2019-11-27","conditions":["Hypertension"],"enrollment":636,"completionDate":"2023-10"},{"nctId":"NCT05470764","phase":"PHASE1","title":"Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-05-30","conditions":["Bioequivalence","Healthy Subjects"],"enrollment":52,"completionDate":"2021-06-28"},{"nctId":"NCT05464745","phase":"PHASE1","title":"Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-05-19","conditions":["Bioequivalence","Healthy Subjects"],"enrollment":42,"completionDate":"2021-06-09"},{"nctId":"NCT05013463","phase":"PHASE2","title":"Hydroxychloroquine and Indapamide in SPMS","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2021-10-01","conditions":["Multiple Sclerosis, Secondary Progressive"],"enrollment":35,"completionDate":"2024-09-01"},{"nctId":"NCT03512392","phase":"NA","title":"Role of Active Deresuscitation After Resuscitation-2","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2018-04-10","conditions":["Critical Illness","Sepsis","Trauma"],"enrollment":180,"completionDate":"2021-07-17"},{"nctId":"NCT05294484","phase":"PHASE4","title":"Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-03-15","conditions":["Pharmacogenomics"],"enrollment":38,"completionDate":"2022-10-01"},{"nctId":"NCT05110898","phase":"PHASE3","title":"Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.","status":"UNKNOWN","sponsor":"Brainfarma Industria Química e Farmacêutica S/A","startDate":"2022-08-01","conditions":["Hypertension","Hypertension,Essential"],"enrollment":400,"completionDate":"2023-10-01"},{"nctId":"NCT05169021","phase":"PHASE4","title":"Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-12-31","conditions":["Cerebral Small Vessel Diseases","Stroke"],"enrollment":15000,"completionDate":"2028-12-31"},{"nctId":"NCT04455178","phase":"PHASE4","title":"The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-09-23","conditions":["Hypertension"],"enrollment":200,"completionDate":"2023-12-31"},{"nctId":"NCT05097794","phase":"PHASE1","title":"A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between \"BR1015-1\" and \"BR1015-2\" in Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-08-16","conditions":["Hypertension"],"enrollment":31,"completionDate":"2021-10-22"},{"nctId":"NCT03722524","phase":"","title":"The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2018-10-01","conditions":["Arterial Hypertension"],"enrollment":1247,"completionDate":"2019-07-17"},{"nctId":"NCT03783754","phase":"NA","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2018-08-09","conditions":["Stroke","Cerebral Small Vessel Diseases","Intracerebral Hemorrhage","Vascular Dementia","Hypertension"],"enrollment":4,"completionDate":"2021-03-21"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT03785067","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2020-02-27","conditions":["Cognitive Decline","Intracerebral Hemorrhage","Dementia, Vascular","Cerebral Small Vessel Diseases","Hypertension","Stroke Hemorrhagic"],"enrollment":1,"completionDate":"2021-02-03"},{"nctId":"NCT03814148","phase":"PHASE3","title":"Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension","status":"WITHDRAWN","sponsor":"EMS","startDate":"2019-06","conditions":["Arterial Hypertension"],"enrollment":0,"completionDate":"2020-09"},{"nctId":"NCT03319823","phase":"PHASE4","title":"Treating Nocturnal Hypertension and Nocturia in African American Men","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-10-25","conditions":["High Blood Pressure"],"enrollment":0,"completionDate":"2021-02-01"},{"nctId":"NCT04686643","phase":"PHASE3","title":"Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension","status":"UNKNOWN","sponsor":"Ahn-Gook Pharmaceuticals Co.,Ltd","startDate":"2021-02-01","conditions":["Hypertension"],"enrollment":306,"completionDate":"2022-05-01"},{"nctId":"NCT03738761","phase":"PHASE4","title":"Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine","status":"COMPLETED","sponsor":"KRKA","startDate":"2018-02-13","conditions":["Hypertension"],"enrollment":471,"completionDate":"2019-09-27"},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":["Hypertension","COVID-19"],"enrollment":2414,"completionDate":"2021-12-01"},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":["The Elderly (≥ 70 Years) With Essential Hypertension"],"enrollment":241,"completionDate":"2019-12-09"},{"nctId":"NCT03626506","phase":"NA","title":"Spironolactone Versus Indapamide in Obese and Hypertensive Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2019-02-13","conditions":["Hypertension"],"enrollment":400,"completionDate":"2020-12"},{"nctId":"NCT03747978","phase":"PHASE4","title":"Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2016-10-01","conditions":["Diabetes Mellitus, Type 2","Hypertension"],"enrollment":30,"completionDate":"2017-05-30"},{"nctId":"NCT03709160","phase":"PHASE4","title":"Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure","status":"UNKNOWN","sponsor":"Centro en Insuficiencia Cardiaca, Mexico","startDate":"2018-10-15","conditions":["Heart Failure","Congestive Heart Failure"],"enrollment":40,"completionDate":"2019-10-15"},{"nctId":"NCT01996085","phase":"NA","title":"Non-invasive Haemodynamic Assessment in Hypertension","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2013-01","conditions":["Arterial Hypertension"],"enrollment":144,"completionDate":"2017-12"},{"nctId":"NCT02539810","phase":"PHASE4","title":"Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":["Hypertension","Hypertension Resistant to Conventional Therapy","Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent"],"enrollment":4,"completionDate":"2017-07"},{"nctId":"NCT01961323","phase":"PHASE4","title":"Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2012-03","conditions":["Hypertension","Left Ventricular Diastolic Dysfunction"],"enrollment":70,"completionDate":"2016-03"},{"nctId":"NCT02655029","phase":"","title":"Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination","status":"COMPLETED","sponsor":"Servier Hellas Pharmaceuticals Ltd.","startDate":"2015-11-25","conditions":["Adherence to Medication Regime","Hypertensive Disease"],"enrollment":2285,"completionDate":"2016-12-21"},{"nctId":"NCT01500590","phase":"PHASE4","title":"Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2011-11","conditions":["Diabetes","Hypertensive Disease"],"enrollment":1400,"completionDate":"2019-08"},{"nctId":"NCT01588795","phase":"PHASE4","title":"Renal Denervation in Diabetic Nephropathy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-04","conditions":["Diabetic Nephropathy","Persistent Proteinuria With Type II Diabetes"],"enrollment":25,"completionDate":"2016-01"},{"nctId":"NCT02710552","phase":"PHASE4","title":"Low-dose Combination of Three Antihypertensive Drugs","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2016-04","conditions":["Arterial Hypertension"],"enrollment":100,"completionDate":"2020-03"},{"nctId":"NCT02710539","phase":"PHASE4","title":"Once-daily Fixed Combination of Three Antihypertensive Drugs","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2016-04","conditions":["Arterial Hypertension"],"enrollment":100,"completionDate":"2020-03"},{"nctId":"NCT01172431","phase":"PHASE4","title":"Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2010-09","conditions":["Hypertension","Renal Insufficiency"],"enrollment":240,"completionDate":"2013-12"},{"nctId":"NCT00980187","phase":"PHASE4","title":"A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM","status":"COMPLETED","sponsor":"LaborMed Pharma S.A.","startDate":"2008-03","conditions":["Hypertension","Type 2 Diabetes Mellitus"],"enrollment":56,"completionDate":"2010-08"},{"nctId":"NCT00664846","phase":"NA","title":"Standard Medical Management in Secondary Prevention of Ischemic Stroke in China","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2008-04","conditions":["Stroke"],"enrollment":4000,"completionDate":"2011-04"},{"nctId":"NCT00670787","phase":"PHASE3","title":"Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2008-06","conditions":["Hypertension"],"enrollment":207,"completionDate":"2011-02"},{"nctId":"NCT00691314","phase":"NA","title":"Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2008-06","conditions":["Stroke","Transient Ischemic Attack","Atherosclerosis","Stenosis","Stents"],"enrollment":300,"completionDate":"2010-12"},{"nctId":"NCT00295542","phase":"PHASE4","title":"Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2000-03","conditions":["Hypertension"],"enrollment":3344,"completionDate":"2009-04"},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":["Hypertension"],"enrollment":52,"completionDate":"2005-09"},{"nctId":"NCT00122811","phase":"PHASE4","title":"The Hypertension in the Very Elderly Trial (HYVET)","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2000-11","conditions":["Hypertension"],"enrollment":4000,"completionDate":"2008-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Indapamide"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Indapamide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147050","MMSL":"2360","NDDF":"002313","UNII":"F089I0511L","VUID":"4018746","CHEBI":"CHEBI:5893","VANDF":"4018746","INN_ID":"3333","RXNORM":"5764","UMLSCUI":"C0021186","chemblId":"CHEMBL406","ChEMBL_ID":"CHEMBL406","KEGG_DRUG":"D00345","DRUGBANK_ID":"DB00808","PDB_CHEM_ID":" BL1","PUBCHEM_CID":"3702","SNOMEDCT_US":"387419003","IUPHAR_LIGAND_ID":"7203","SECONDARY_CAS_RN":"180004-24-4","MESH_DESCRIPTOR_UI":"D007190"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Sanofi","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"90%"},"publicationCount":1378,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"C03BA11","allCodes":["C03BA11","C09BX01","C10BX13"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 26","pmid":"41746376","title":"Pure vs. mixed calcium oxalate nephrolithiasis: metabolic determinants and stratified management strategies.","journal":"World journal of urology"},{"date":"2025 Dec","pmid":"41728364","title":"2024 Thai guidelines on the treatment of hypertension.","journal":"Asian biomedicine : research, reviews and news"},{"date":"2026 Feb 11","pmid":"41667119","title":"Quadruple vs triple therapy for resistant hypertension: the QUADRO trial.","journal":"European heart journal"},{"date":"2026 Feb","pmid":"41656849","title":"Effectiveness of Indapamide Prolonged-Release and Perindopril Versus Perindopril Monotherapy for Treated Uncontrolled Hypertension: A Target Trial Emulation.","journal":"Pharmacoepidemiology and drug safety"},{"date":"2026 Jan 28","pmid":"41593840","title":"Widaplik: A Fixed-Dose Triple Combination for Initial Hypertension Therapy.","journal":"Cardiology in review"}],"companionDiagnostics":[],"genericManufacturers":7,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Elizabeth","Ani Pharms","Aurobindo Pharma Usa","Chartwell Rx","Rising","Teva","Watson Labs"],"status":"approved","companyName":"Sanofi Aventis Us","companyId":"","modality":"Small molecule","firstApprovalDate":"1983","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1983-07-06T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-06-17T00:00:00.000Z","mah":"ACTAVIS ELIZABETH","brand_name_local":null,"application_number":"ANDA074722"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-03-26T00:00:00.000Z","mah":"RISING","brand_name_local":null,"application_number":"ANDA074461"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-11-23T00:00:00.000Z","mah":"ANI PHARMS","brand_name_local":null,"application_number":"ANDA074299"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-06-05T00:00:00.000Z","mah":"AZURITY","brand_name_local":null,"application_number":"NDA219423"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:40:12.852486+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}